adaptive biotechnologies stock analysis

ADPT is down -024 from the previous closing price of 3271 on volume of 145894 shares. Analyst Price Target on ADPT.

Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha

The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease.

. ADPT shares are trading higher by 1258 to 725 after the company launched T-Detect Lyme to help diagnose early lyme disease. Adaptive Biotechnologies Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stocks chart. Adaptive Biotechnologies Corporation is a commercial-stage company.

Adaptive Biotechnologies has a beta of 092 meaning that its stock price is 8 less volatile than the SP 500. Adaptive Biotechnologies Corp NASDAQ. Learn about Adaptive Biotechnologies Corp ADPTXNAS stock quote with Morningstars rating and analysis and stay up to date with the current news price valuation dividends and other stock.

Open an Account Today. The average price target is 1630 with a high forecast of 2500 and a low forecast of 750. May 11 2022 at 840 AM PDT.

ADPT Stock Overview Adaptive Biotechnologies Corporation a commercial-stage company develops an immune medicine platform for the diagnosis and treatment of various diseases. View todays Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Exclusive research and insights from bulls and bears.

Adaptive Biotechnologies Corp ADPT stock has fallen -075 while the SP 500 is higher by 052 as of 1150 AM on Monday Oct 11. BofA Securities 2022 Healthcare Conference. 3 weeks ago - Benzinga Adaptive Biotechnologies launches T cell-based test for Lyme disease.

In-depth view of key statistics and finances for ADAPTIVE BIOTECHNOLOGIES CORPORATION ADPT on MSN Money. Its immune medicine platform combines a suite of chemistry biology and machine learning to generate clinical immunomics. Review the latest analysis on Adaptive Biotechnologies Corp ADPTXNAS stock to find out if this stock is best investment for you based on Morningstars analysis.

However a hammer chart pattern was formed in its last trading session which could. Adpt a commercial-stage biotechnology company that aims to translate the genetics of. 5673 Upside Based on 5 Wall Street analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months.

Learn How to Make Your Saving Goals a Reality. Seattle july 08 2022 globe newswire -- adaptive biotechnologies corporation nasdaq. Over the past year the SP 500 is higher by 2490 while ADPT is down -3859.

A high-level overview of Adaptive Biotechnologies Corporation ADPT stock. Comparatively PharmaCyte Biotech has a. Comparatively PharmaCyte Biotech has a.

Real time Adaptive Biotechnologies Corporation ADPT stock price quote stock graph news analysis. According to analysts consensus price target of 2608 Adaptive Biotechnologies has a forecasted upside of 2563 from its current price of 732. InvestorsObserver gives Adaptive Biotechnologies Corp ADPT an overall rank of 41 which is below average.

About the company Rewards Revenue is forecast to grow 2417 per year Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years. William Blair 42nd Annual Growth Stock Conference Presentation 48 MB. Amount of Analyst Coverage Adaptive Biotechnologies has only been the subject of 2 research reports in the past 90 days.

Ad Searching for Financial Security. Adaptive Biotechnologies Corporation a commercial-stage company develops an immune medicine platform for the diagnosis and treatment of various diseases. View real-time ADPT stock price and news along with industry-best analysis.

Adaptive Biotechnologies Stock analysis including Adaptive Biotechnologies investment evaluation stock information alerts predictive tools such as market volatility and liquidity estimators and more. Stock information by Barrons. So its worth taking a look at the surprise history for gauging its influence on the upcoming numberfor the last reported quarter it was expected that adaptive biotechnologies would post a loss.

Ad No Hidden Fees. S hares of Adaptive Biotechnologies ADPT have been struggling lately and have lost 154 over the past week. Create real-time notifications to follow any changes in the live stock price.

Stay up to date on the latest stock price chart news analysis fundamentals trading. Profit With Faster Market News Research. Adaptive Biotechnologies says in.

Ad Get the Inside Access Traders Are Using to Profit More and Win Bigger. A rank of 41 means that 59 of stocks appear more favorable to our system. Make Informed Trades Before Share Prices React.

The company offers immunoSEQ a platform and core immunosequencing product that is used to answer translational research questions as well as to discover new prognostic and. Complete Adaptive Biotechnologies Corp. Find the latest Adaptive Biotechnologies Corporation ADPT stock analysis from Seeking Alphas top analysts.

Adaptive Biotechnologies has a beta of 092 meaning that its stock price is 8 less volatile than the SP 500. See Adaptive Biotechnologies Corporation ADPT stock analyst estimates including earnings and revenue EPS upgrades and downgrades. Stock Symbol ADPT Investments 1 Share Price 957 As of Wednesday Closing General Information Description Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

The average price target represents a 5673 change from the last price of 1040. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune system into clinical products to diagnose and treat disease. See Top Rated MarketRank Stocks Here.

Find Out What Services a Dedicated Financial Advisor Offers.

Adaptive Biotechnologies Corporation Adpt Stock Price Quote News Stock Analysis